CITIUS ONCOLOGY, INC. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 38/100
What the filing says
Citius Oncology presented exploratory quality-of-life data from Study 302 supporting FDA-approved LYMPHIR (denileukin diftitox-cxdl) for relapsed/refractory cutaneous T-cell lymphoma at the EORTC-CLTG conference in Berlin on October 8–10, 2026. Among 25 responders (of 69 Stage I–III patients), Skindex-29 skin quality-of-life scores improved 5.38–13.69 points vs. non-responders; 32% of 41 heavily pretreated patients with baseline itch ≥20 mm achieved ≥20 mm decrease. The company launched LYMPHIR in December 2025; management estimates the initial CTCL market at >$400 million.
Why this rating
Positive clinical data supports commercialization of already-approved product; however, exploratory nature (not powered, no formal stats) limits impact. Modest market validation for $5.1M company with nascent revenue; material only if drives uptake and reimbursement.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.